Ibrutinib has proven to be very effective in newly diagnosed and relapsed chronic lymphocytic leukemia (CLL) patients. However, it can cause certain side effects that can lead to early discontinuation of treatment and worse outcomes for patients. The goal of this study is to determine the frequency of side effects in the “real-world” associated with […]
Read More